Sygnature Discovery Boosts DMPK Capabilities with Four Senior Appointments
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has recruited four key individuals to boost its DMPK (drug metabolism and pharmacokinetics) capabilities. Dr Stuart Best, Dr Hayley Butler, Dr Daniel Weston and Dr Bodo Spöri have all joined the senior management team of the company’s DMPK department. Dr Stuart Best joins as Associate Director of DMPK and will manage and supervise the growth of the Alderley Park-based part of the DMPK team, which opened in 2018.…
You might be interested in
